| Formulary Chapter 14: Immunological products and vaccines - Full Chapter
|
| Notes: |
Prescribing Guidance
Please see our Prescribing Guidelines page for all prescribing guidance relating to this chapter.
Shared Care Agreements
There are no Shared Care Agreements relating to this chapter.
|
|
|
| Chapter Links... |
 Complete routine immunisation schedule |
| Covid-19 vaccines: General information and guidance |
| HPA: Vaccine incident guidance- actions to take in response to vaccine errors 2019 |
| Immform Portal |
| PGDs for immunisations in primary care |
| PHE - Green Book |
| PHE Vaccine Update (produced monthly) |
| Protocol for ordering, storing and handling vaccines |
| Vaccination of individuals with uncertain or incomplete immunisation status (Updated Oct 2019) |
| National Immunoglobulin Database |
| Details... |
| 14.04 |
Vaccines and antisera |
|
|
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection
(Pfizer/BioNTech COVID-19 vaccine)
|
Formulary
 
|
- This medicinal product has been given authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines & Healthcare products Regulatory Agency. It does not have a marketing authorisation, but this temporary authorisation grants permission for the medicine to be used for active immunization to prevent COVID-19 disease caused by SARS-CoV-2 virus in individuals aged 16 years of age and over.
- This is a multidose vial and must be diluted before use. 1 vial (0.45 mL) contains 6 doses of 30 micrograms of BNT162b2 RNA (embedded in lipid nanoparticles).
- COVID-19 mRNA Vaccine BNT162b2 is administered intramuscularly after dilution as a series of two doses (0.3 mL each) at least 21 days apart.
- Preparation: The multidose vial is stored frozen and must be thawed prior to dilution.
- For further information see link below.
|
 MHRA DSU Jan 2021COVID-19 vaccines (Pfizer/BioNTech and COVID-19 Vaccine AstraZeneca): current advice
MHRA Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine Jan 2021
|
COVID-19 Vaccine AstraZeneca
(Solution for injection in multidose container)
|
Formulary
|
- This medicinal product has been given authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency. It does not have a marketing authorisation, but this temporary authorisation grants permission for the medicine to be used for active immunisation of individuals aged 18 years and older for the prevention of coronavirus disease 2019 (COVID-19).
- The COVID-19 Vaccine AstraZeneca vaccination course consists of two separate doses of 0.5 ml each. The second dose should be administered between 4 and 12 weeks after the first dose.
- COVID-19 Vaccine AstraZeneca is for intramuscular (IM) injection only, preferably in the deltoid muscle.
- Store in a refrigerator (2 to 8°C).
- For further information see below.
|
MHRA DSU Jan 2021 COVID-19 vaccines (Pfizer/BioNTech and COVID-19 Vaccine AstraZeneca): current advice
MHRA Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca Jan 2021
|
| 14.04 |
Anthrax vaccine |
|
|
| 14.04 |
BCG vaccines |
|
|
BCG vaccine diagnostic agent
|
Formulary
|
- Tuberculline purified protein derivative (PPD) (Mantoux test) - named patient.
|
Green book chapter 32
|
BCG vaccine Intradermal
|
Formulary
|
- Bacillus calmette-guerin vaccine
- The BCG vaccine (which stands for Bacillus Calmette-Guérin vaccine) is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB
|
Green Book - Chapter 32
NHSE items that should not be prescribed in primary care quick guide (includes some vaccines)
|
| 14.04 |
Botulism antitoxin |
|
|
| 14.04 |
Cholera vaccine |
|
|
Cholera vaccine
(Dukoral®)
|
Formulary
|
- This vaccine is not indicated for most travellers
|
Green Book - Chapter 14
|
| 14.04 |
Diphtheria vaccines |
|
|
Boostrix IPV ®
|
Formulary
|
- Boostrix-IPV suspension for injection in pre-filled syringe
- Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content) (schedule between 3yrs & 4/12 to 5 years)
|
SPS Change of maternal pertussis vaccine, Jan 2020
|
Infanrix hexa ®
|
Formulary
|
- Powder and suspension for suspension for injection.
- Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed).
- Infanrix hexa is indicated for primary and booster vaccination of infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b.
- (schedule at 2, 3, 4 months)
|
|
|
Infanrix IPV ®
|
Formulary
|
- Infanrix®-IPV, suspension for injection in pre-filled syringe
- Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed) (schedule between 3yrs & 4/12 to 5 years)
|
|
|
Pediacel ®
|
Formulary
|
- Suspension for injection in pre-filled syringe
- Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed)
|
|
|
Repevax ®
|
Formulary
|
- Suspension for injection, in pre-filled syringe
- Diphtheria, Tetanus, Pertussis (acellular, component) and Poliomyelitis (inactivated) Vaccine (adsorbed, reduced antigen(s) content) (schedule between 3yrs & 4/12 to 5 years)
|
|
|
Revaxis ®
|
Formulary
|
- Suspension for injection in pre-filled syringe
- Diphtheria, tetanus and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content. (schedule 13-18 yrs and adults if not previously immunised)
|
|
|
| 14.04 |
Haemophilus influenzae type B vaccine |
|
|
Haemophilus influenzae type B Combined Vaccine
(Menitorix®)
|
Formulary
|
|
Green Book _ Chapter 16
|
| 14.04 |
Hepatitis A vaccine |
|
|
Hepatitis A vaccine Single Component
(Avaxim®)
|
Formulary
|
|
Green Book - Chapter 17
|
Hepatitis A vaccine Single Component
(Havrix Monodose®)
|
Formulary
|
|
Green Book - Chapter 17
|
Hepatitis A vaccine Single Component
(Vaqta® )
|
Formulary
|
|
Green Book - Chapter 17
|
Hepatitis A vaccine with Hepatitis B vaccine
(Ambirix ®)
|
Formulary
|
- Hepatitis B NOT routinely available on the NHS for the purposes of travel therefore combination vaccine not commissioned locally on the NHS.
|
|
|
Hepatitis A vaccine with Hepatitis B vaccine
(Twinrix®)
|
Formulary
|
- Adult and Paediatric
- Hepatitis B NOT routinely available on the NHS for the purposes of travel therefore combination vaccine not commissioned locally on the NHS.
|
|
|
Hepatitis A vaccine with typhoid vaccine
(VIATIM®)
|
Formulary
|
|
|
|
| 14.04 |
Hepatitis B vaccine |
|
|
Hepatitis B vaccine Single Component
(Engerix B®)
|
Formulary
|
- This vaccine is not available at NHS expense in Wiltshire/Bath/Swindon for Overseas Travel
|
Green Book - Chapter 18
|
Hepatitis B vaccine Single Component
(Fendrix®)
|
Formulary
|
- Bath - not on formulary
- This vaccine is not available at NHS expense in Wiltshire/Bath/Swindon for Overseas Travel
|
Green Book - Chapter 18
|
Hepatitis B vaccine Single Component
(HBvaxPRO®)
|
Formulary
|
- This vaccine is not available at NHS expense in Wiltshire/Bath/Swindon for Overseas Travel
|
Green Book - Chapter 18
|
| 14.04 |
Human papilloma virus vaccine |
|
|
Human papilloma virus vaccine
(Gardasil®)
|
First Choice
|
- Vaccine of choice for the national immunisation program (see Green Book)
- a quadravalent vaccine which also covers anal lesions, anal cancer and genital warts
- Gardasil is currently the only HPV vaccine supplied for the national HPV programme (for both adolescents and men who have sex with men).
|
Green Book - Chapter 18a
|
| 14.04 |
Influenza vaccine |
|
|
|
Influenza vaccine
|
Formulary
|
- Brands include: Inactivated Influenza Vaccine (Split Virion), Agrippal CSL, Inactivated Influenz Vaccine Enzira Imuvac Influvac, Fluarix Tetra, Fluad
|
Green Book - Chapter 19
Vaccine ordering for 2019-20 influenza season: letters
|
Influenza vaccine ®
(Fluenz Tetra)
(nasal)
|
Formulary
|
- Primary Care Only : Please note that flu vaccines for children should be ordered via IMMFORM and should NOT be reclaimed via NHS prescription services (PPA).
|
|
|
| 14.04 |
Measles vaccine |
|
|
| 14.04 |
Measles, Mumps and Rubella (MMR) vaccine |
|
|
Measles, Mumps and Rubella Vaccine, Live (MMR)
(MMRvaxPro® Priorix®)
|
Formulary
|
|
PHE Jan 2014: Measles, mumps, rubella (MMR): use of combined vaccine instead of single vaccines
|
| 14.04 |
Meningococcal vaccines |
|
|
Meningococcal polysaccharide A, C, W135 and Y vaccine
(ACWY Vax®)
|
Formulary
|
- This vaccine is not available at NHS expense in Wiltshire/Bath/Swindon for Overseas Travel
|
Green Book - Chapter 22
NHSE Items which should not be routinely prescribed in primary care (includes some vaccines)
|
Meningococcal A, C, W135, and Y conjugate vaccine
(Menveo®)
|
Formulary
|
- Menveo powder and solution for solution for injection
- Meningococcal Group A, C, W-135 and Y conjugate vaccine
- This vaccine is not available at NHS expense in Wiltshire/Bath/Swindon for Overseas Travel
|
Green Book - Chapter 22
NHSE Items which should not be routinely prescribed in primary care (includes some vaccines)
|
Meningococcal group A, C, W-135 and Y conjugate vaccine
(Nimenrix®)
|
Formulary
|
- This vaccine is not available at NHS expense in Wiltshire/Bath/Swindon for Overseas Travel
|
Green Book - Chapter 22
NHSE Items which should not be routinely prescribed in primary care (includes some vaccines)
|
Meningococcal group B Vaccine
(Bexsero®)
|
Formulary
|
|
Green Book - Chapter 22
|
Meningococcal Group C Polysaccharide Conjugate Vaccine Adsorbed
(NeisVac-C®)
|
Formulary
|
|
Green Book- Chapter 22
|
| 14.04 |
Mumps vaccine |
|
|
| 14.04 |
Pertussis vaccine |
|
|
| 14.04 |
Pneumococcal vaccines |
|
|
23-valent pneumococcal polysaccharide vaccine
(Previously known as Pneumovax® II)
|
Formulary
|
- Primary Care: at NHS expense for patients in accordance with the national immunisation programme. Adults over 65 years and at risk groups, as listed in the Green Book, chapter 25.
- Use practice stock and claim on FP34 appendix form.
|
Green Book - Chapter 25
|
Pneumococcal polysaccharide conjugate vaccine (adsorbed)
(Prevenar 13®)
|
Formulary
|
- Primary Care: at NHS expense for infants as part of the routine childhood immunisation programme (order free of charge via Immform)
|
Green Book - Chapter 25
|
| 14.04 |
Poliomyelitis vaccines |
|
|
| 14.04 |
Rabies vaccine |
|
|
Rabies vaccine
(Rabipur®)
|
Formulary
|
- Only on formulary for NHS use for Rabies Post-Exposure treatment in accordance with PHE guidelines.
- This immunisation is not remunerated by the NHS as part of additional services and is available from Private Clinics (prices may vary) if used for travel purposes (pre-exposure).
|
PHE: Guidelines on managing rabies post-exposure April 2019
|
| 14.04 |
Rotavirus vaccine |
|
|
Rotavirus vaccine
(Rotarix®)
|
Formulary
|
|
Green Book - Chapter 27b
|
| 14.04 |
Rubella vaccine |
|
|
| 14.04 |
Smallpox vaccine |
|
|
| 14.04 |
Tetanus vaccines |
|
|
| 14.04 |
Tick-borne encephalitis vaccine |
|
|
Tick-borne encephalitis vaccine
(TicoVac ®)
|
Formulary
|
- Available on a named patient basis from MASTA
- This immunisation is not remunerated by the NHS as part of additional services and is available from Private Clinics (prices may vary).
|
|
|
| 14.04 |
Typhoid vaccines |
|
|
Polysaccharide Typhoid Vaccine
(Typherix®)
|
Formulary
|
|
Green Book - Chapter 33
|
Polysaccharide vaccine for injection
(Typhim Vi®)
|
Formulary
|
|
Green Book - Chapter 33
|
| 14.04 |
Varicella-zoster vaccine |
|
|
Varicella Zoster vaccine
(Zostavax®)
|
Formulary
|
- The aim of the national shingles immunisation programme is to lower the incidence and severity of shingles in older people. It is recommended that it be routinely offered to people aged 70 years.
- Whilst the vaccine is authorised for use from age 50 years and is effective in this age group, the burden of shingles disease is generally not as severe in those aged 50-69 years when compared with older ages. Furthermore, given that the duration of protection is not known to last for more than ten years and the need for a second dose is not known, the vaccine is not recommended to be offered routinely below 70 years of age. Administration after 80 years of age is less cost-effective due to the limited effectiveness of the vaccine in older individuals.
|
Green Book - Chapter 28a
|
Varicella-zoster vaccine
(Varilrix®)
|
Formulary
|
- Varilrix is indicated for active immunisation against varicella of healthy subjects (from the age of 9 months).
- Vaccination of susceptible healthy close contacts of subjects at risk of severe varicella is recommended, in order to reduce the risk of transmission of wild-type virus to these patients. Close contacts include parents and siblings of high-risk patients, and medical and paramedical personnel.
- Use as per green book only.
|
Green Book - Chapter 34
|
Varicella-zoster vaccine
(Varivax®)
|
Formulary
|
- VARIVAX is indicated for vaccination against varicella in individuals from 12 months of age.
- VARIVAX can be administered to infants from 9 months of age under special circumstances, such as to conform with national vaccination schedules or in outbreak situations.
- VARIVAX may also be administered to susceptible individuals who have been exposed to varicella. Vaccination within 3 days of exposure may prevent a clinically apparent infection or modify the course of the infection. In addition, there are limited data that indicate that vaccination up to 5 days after exposure may modify the course of the infection
- Use as per green book only.
|
Green Book - Chapter 34
|
| 14.04 |
Yellow fever vaccine |
|
|
Yellow fever vaccine (Live)
(Stamaril ®)
|
Formulary
|
- This immunisation is not remunerated by the NHS as part of additional services and is available from Private Clinics (prices may vary):
|
MHRA November 2019 Yellow fever vaccine: stronger precautions in people with weakened immunity and in those aged 60 years or older
MHRA April 2019 - Stamaril extreme caution needed in people who may be immunosuppressed and those 60 years and older
|
| .... |
| Non Formulary Items |
Anthrax vaccine
|
Non Formulary
|
|
|
|
Botulism antitoxin
|
Non Formulary
|
|
|
|
Hepatitis A vaccine Single Component
(Epaxal®)
|
Non Formulary
|
DISCONTINUED |
Green Book - Chapter 17
|
Hepatitis A vaccine with typhoid vaccine
(Hepatyrix®)
|
Non Formulary
|
DISCONTINUED |
|
|
Japanese Encephalitis Vaccine
(Ixiaro®)
|
Non Formulary
|
- This vaccine is not available at NHS expense in Wiltshire/Swindon/Bath for Overseas Travel.
|
|
|
Malaria vaccine
(Mosquirix®)
|
Non Formulary
|
|
|
|
Meningococcal Group C Polysaccharide Conjugate Vaccine Adsorbed
(Menjugate ®)
|
Non Formulary
|
DISCONTINUED |
Green Book- Chapter 22
|
| |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
High Cost Drug Approval System |
|
Traffic Light Status Information
|
|
|
